Ameriprise Financial Inc Aadi Bioscience, Inc. Transaction History

Ameriprise Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.97 - $5.41 $94,203 - $258,700	-47,819 Reduced 31.6%	103,489 $209,000
Q3 2023 Nov 14, 2023	BUY	$4.84 - $7.13 $1,592 - $2,345	329 Added 0.22%	151,308 $732,000
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $376,425 - $471,082	55,033 Added 57.36%	150,979 $1.03 Million
Q1 2023 May 15, 2023	BUY	$6.85 - $13.0 $254,621 - $483,223	37,171 Added 63.24%	95,946 $694,000
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $704,712 - $852,237	58,775 New	58,775 $754,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $46.7M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.